ClinicalTrials.Veeva

Menu

Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia

Ono Pharmaceuticals logo

Ono Pharmaceuticals

Status and phase

Completed
Phase 2

Conditions

Community-acquired Pneumonia

Treatments

Drug: ONO-5046Na

Study type

Interventional

Funder types

Industry

Identifiers

NCT00417326
ONO-5046Na-14

Details and patient eligibility

About

The purpose of this study is to determine the safety and efficacy of ONO-5046Na in patients with acute respiratory failure associated with community-acquired pneumonia

Enrollment

174 patients

Sex

All

Ages

20 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with community-acquired pneumonia
  • Patients with acute respiratory failure

Exclusion criteria

  • Patients with nosocomial pneumonia
  • Patients on mechanical ventilation

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

174 participants in 2 patient groups, including a placebo group

P
Placebo Comparator group
Treatment:
Drug: ONO-5046Na
Drug: ONO-5046Na
E
Experimental group
Treatment:
Drug: ONO-5046Na
Drug: ONO-5046Na

Trial contacts and locations

9

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems